Case Western Reserve Medical School
Case Western Reserve University - Neurology
Case Western Reserve University
Cleveland VA Medical Center- neuroscience research
Clinical / Research Interests
Myasthenia Gravis

Henry J. Kaminski, MD is board-certified in Neurology, the Meta Amalia Neumann professor of the Department of Neurology at The George Washington University School of Medicine & Health Sciences. He most recently served as professor and chair of the Department of Neurology and Psychiatry and director of the Clinical Research Unit at St. Louis University. He is an internationally recognized expert in the care of patients with myasthenia gravis, a chronic autoimmune neuromuscular disease characterized by varying degrees of weakness of the skeletal (voluntary) muscles of the body. His research, which has been funded by the National Institutes of Health since 1993, focuses on understanding the biology of the extraocular muscles and the pathogenesis of myasthenia gravis.

Dr. Kaminski is the author of more than 100 peer-reviewed articles and book chapters and serves as the editor of Myasthenia Gravis and Related Disorders, which is now in its second edition, and of Neuromuscular Disorders in Clinical Practice, one of the only comprehensive texts in the field of neuromuscular disease. He serves as councilor for the American Neurological Association, president of the Association of University Professors of Neurology, and chair of the Myasthenia Gravis Foundation of America scientific board. He is also a fellow of the American Academy of Neurology.

Dr. Kaminski received both his BA and MD from Case Western Reserve University, and performed his internship in Internal Medicine and his residency in Neurology at the University Hospitals of Cleveland.He spent most of his career at Case Western Reserve University, where medical students elected him to the Alpha Omega Alpha honor society for his dedication and excellence to teaching. During his time in Cleveland, he also was chief of the Neurology Service at the Cleveland Veterans Affairs Medical Center and was awarded several performance awards for his work in the care of veterans.

Clinical Trials

This is a phase II, single center, randomized, double-blind, placebo-controlled, study in patients with a diagnosis of anti-AchR antibody positive myasthenia gravis to compare the gastrointestinal (GI) side effects.

Study RA101495-02.302 is a multicenter, open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study.

This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab compared with placebo in participants with generalized myasthenia gravis (gMG).